Growth hormone’s influence on neuropsychiatric disorders
The discovery of a mechanism involving anxiolytic effects of GH may lead to the development of new classes of anxiolytic drugs.
List view / Grid view
The discovery of a mechanism involving anxiolytic effects of GH may lead to the development of new classes of anxiolytic drugs.
Dr William Schafer, of the MRC Laboratory of Molecular Biology, focuses on the cellular and molecular mechanisms of behaviour, which is one of the fundamental problems of biology. Schafer and his colleagues have studied the nematode Caenorhabditis elegans, using a variety of approaches such as optogenetic neuroimaging and high content…
US scientists offer a new purpose for the blood pressure drug clonidine as a treatment to reduce the affects of PTSD.
The findings provide insight into how genetics can make someone more susceptible to developing PTSD following trauma exposure.
In this exclusive piece, Adrien Châtillon, Co-Founder and CEO of Actipulse Neuroscience, explores the future of treatment for diseases that impact mental health.
A non-hallucinogenic version of the psychedelic drug ibogaine could treat psychiatric disorders, pre-clinical trials have shown.
A study has identified a protein complex elevated in PTSD patients and developed a peptide to disrupt it, preventing the recall of fear memories in early tests and paving the way for new therapies.
Researchers in the U.S. have identified a new link between epigenetic changes in the brains of rats and resulting translational control during fear memory reconsolidation.
Harvard University researchers have developed a multiregional brain-on-a-chip that models the connectivity between three distinct regions of the brain.
17 August 2016 | By Niamh Louise Marriott, Digital Content Producer
Recent studies show that sleep disturbance is not only a negative outcome from PTSD, it may also contribute to its onset...
4 August 2016 | By Niamh Marriott, Digital Content Producer
Chronos Therapeutics, a biotech company researching ageing diseases, brain and nervous system disorders, have announced the appointment of Dr Fraser Murray and Dr Timothy Schulz-Utermoehl, as Vice Presidents of Pre-Clinical Development...
12 May 2016 | By Victoria White, Digital Content Producer
The UT Health Science Centre at San Antonio has filed for patent protection on the finding because it may eventually lead to a drug to treat PTSD...
28 October 2015 | By Victoria White
Experimentally reducing SGK1 activity in rats induced learned helplessness ( a behaviour thought to mimic one aspect of PTSD), while overexpressing the protein reduced it...
17 August 2015 | By Victoria White
Genetically altered mice could form the basis for research into new treatments for cognitive disorders such as Alzheimer’s disease and schizophrenia...